PER2 and hepatocellular carcinoma: Nevertheless, the role of PER2 expression and modulation in drug resistance remains poorly understood in HCC, mainly due to the difficulty in obtaining tissue samples from patients with unresectable HCC in the advanced stage (BCLC stage C), for whom the treatment with TKIs is typically indicated.